Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia.
Raquel DelgadoKaroline KielbassaJohanna Ter BurgChristiane NeumannChristine TrumpfhellerKoen de HeerArnon P KaterEric ElderingPublished in: Cancers (2021)
Taken together, these novel insights into selicrelumab-stimulatory effects in CLL may be considered for developing new therapeutic strategies, particularly in combination with obinutuzumab.